Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Alle...

FDA Recall #D-0154-2018 — Class II — December 4, 2017

Recall #D-0154-2018 Date: December 4, 2017 Classification: Class II Status: Terminated

Product Description

Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Allergan USA Inc., Irvine, CA 92612, Manufactured in Canada, NDC 58914-117-10

Reason for Recall

Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.

Recalling Firm

ALLERGAN — Madison, NJ

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

12,699 bottles

Distribution

U.S.A. nationwide

Code Information

Lot #: 160741A, Exp 02/18

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated